

HuaMedicine
华领医药

“ ”


1 2
3 4 5
6 7 8


a

b

Copyright © Hua Medicine 2023


H
H M





7030


299.6%


Q1 4

Q3 8

Copyright © Hua Medicine 2023


H
H M





GLP-1

DREAM SEED 2

65%

52

GK


GK

TIR

IGT


Source: Chen L, Zhang JY et al. Nature Communications , A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity 2023, 3 1405.

Copyright © Hua Medicine 2023






GLP-1



GLP-1

Copyright © Hua Medicine 2023


Copyright © Hua Medicine 2023




Copyright © Hua Medicine 2023

Goto-Kakizaki


26 GK






Copyright © Hua Medicine 2023

HFD /






19

19 10 18 38

45


Copyright © Hua Medicine 2024

24



TIR 46 83.7%

TIR





TIR

Diabetes Obes Metab.2023 Jun 29. doi: 10.1111/dom.15179

Copyright © Hua Medicine 2024


H
H M



Copyright © Hua Medicine 2023


GKA

1

β

GKA


β



Copyright © Hua Medicine 2023

4.7 15





Copyright © Hua Medicine 2023



GLP-1RA

AI

Copyright © Hua Medicine 2023

2023

Q4

Copyright © Hua Medicine 2023


H M
A

____ 2023 70.3


® 2023 6 30 ® 212


000 70.3 2022 299.6%

2023 6 30 265,000 ® 87.9

____ 2023 44.0 62.6%

43.7% 18.9%





Copyright © Hua Medicine 2023

2023 38.6

2022 21.4 17.2 2023
21.7 6.2
10.7

2023 90.1 2022 14.5

2023 / Ņ Ƒ

Copyright © Hua Medicine 2023

_____ 2022 6 30 72.3 1.3 2023 6 30
71.0

- Dorzagliatin 2022 6 30 0.8 3.2 2023
6 30 4.0 2023 2022

- 2022 6 30 9.0 2.9 2023 6 30

)D2'¶) I#-õ+9ü3hR9÷H/ UgFj`&¦r”FVž"ß(ïŸÃ2 Vt “Sde^Ð

2023

Copyright © Hutchmed 2023

Copyright © Hua Medicine 2023

